Bristol-Myers Squibb (BMY) Shares Bought by Orbis Allan Gray Ltd

Orbis Allan Gray Ltd increased its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 31.1% during the fourth quarter, HoldingsChannel reports. The firm owned 6,901,670 shares of the biopharmaceutical company’s stock after buying an additional 1,635,666 shares during the period. Bristol-Myers Squibb comprises 2.5% of Orbis Allan Gray Ltd’s portfolio, making the stock its 16th biggest holding. Orbis Allan Gray Ltd’s holdings in Bristol-Myers Squibb were worth $422,935,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Delphi Private Advisors LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $108,000. Massey Quick Simon & CO. LLC lifted its holdings in shares of Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares in the last quarter. Horan Capital Advisors LLC. bought a new position in shares of Bristol-Myers Squibb during the third quarter valued at $122,000. NuWave Investment Management LLC bought a new position in shares of Bristol-Myers Squibb during the fourth quarter valued at $119,000. Finally, Atlantic Trust LLC bought a new position in shares of Bristol-Myers Squibb during the second quarter valued at $111,000. 71.51% of the stock is currently owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of BMY opened at $62.31 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.55 and a quick ratio of 1.43. The stock has a market capitalization of $102,820.08, a price-to-earnings ratio of 20.92, a P/E/G ratio of 1.64 and a beta of 0.96. Bristol-Myers Squibb has a 52 week low of $51.56 and a 52 week high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping analysts’ consensus estimates of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. The business’s quarterly revenue was up 3.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.63 earnings per share. research analysts anticipate that Bristol-Myers Squibb will post 3.22 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, May 1st. Shareholders of record on Friday, April 6th will be given a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 2.57%. The ex-dividend date is Thursday, April 5th. Bristol-Myers Squibb’s payout ratio is 53.16%.

BMY has been the subject of a number of research reports. BMO Capital Markets set a $49.00 price objective on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday, December 11th. Vetr cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $59.70 price objective for the company. in a research report on Friday, December 22nd. Zacks Investment Research cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Credit Suisse Group set a $62.00 price objective on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Finally, Leerink Swann upped their price objective on Bristol-Myers Squibb from $71.00 to $76.00 and gave the company a “positive” rating in a research report on Tuesday, February 6th. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have given a buy rating to the stock. Bristol-Myers Squibb presently has an average rating of “Hold” and a consensus target price of $66.68.

TRADEMARK VIOLATION NOTICE: “Bristol-Myers Squibb (BMY) Shares Bought by Orbis Allan Gray Ltd” was first reported by Ticker Report and is the property of of Ticker Report. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.tickerreport.com/banking-finance/3334380/bristol-myers-squibb-bmy-shares-bought-by-orbis-allan-gray-ltd.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Rentokil Initial  Stock Rating Lowered by Deutsche Bank
Rentokil Initial Stock Rating Lowered by Deutsche Bank
Nielsen  Stock Rating Upgraded by BMO Capital Markets
Nielsen Stock Rating Upgraded by BMO Capital Markets
Countryside Properties  Price Target Raised to GBX 410
Countryside Properties Price Target Raised to GBX 410
Randgold Resources  Given a $100.00 Price Target at Desjardins
Randgold Resources Given a $100.00 Price Target at Desjardins
The J.M. Smucker  Cut to “Sell” at Credit Suisse Group
The J.M. Smucker Cut to “Sell” at Credit Suisse Group
Sensient Technologies  Earning Somewhat Positive News Coverage, Study Finds
Sensient Technologies Earning Somewhat Positive News Coverage, Study Finds


Leave a Reply

© 2006-2018 Ticker Report. Google+.